Table 3

Baseline patient characteristics
All wild-type KRAS codon 12, 13 mutations KRAS codon 61, codon 146, BRAF, NRAS or PIK3CA mutations (any other mutations)
(N= 49) (N= 21) (N= 12)
Treatment
Cetuximab + irinotecan (%) 47 (96) 19 (90) 10 (83) P = 0.212
Cetuximab monotherapy (%) 2 (4) 2 (10) 2 (17)
Age
Median (range) 61 (29–78) 65 (51–80) 65 (43–76) P = 0.605
Gender
Male (%) 31 (63) 16 (76) 6 (50) P = 0.312
Female (%) 18 (37) 5 (24) 6 (50)
ECOG PS
0 (%) 34 (69) 13 (62) 5 (42) P = 0.185
1–2 (%) 15 (31) 8 (38) 7 (58)
Primary lesion
Colon (%) 28 (57) 15 (71) 9 (75) P = 0.416
Rectum (%) 21 (43) 6 (29) 3 (25)
Site of Metastasis
Liver
Yes (%) 33 (67) 13 (62) 8 (67) P = 0.945
No (%) 16 (33) 8 (38) 3 (33)
Lung
Yes (%) 34 (69) 15 (71) 9 (75) P = 1.000
No (%) 15 (31) 6 (29) 3 (25)
Lymph node
Yes (%) 26 (53) 7 (33) 9 (75) P = 0.068
No (%) 23 (47) 14 (67) 3 (25)
Peritoneum
Yes (%) 11 (22) 3 (14) 2 (17) P = 0.791
No (%) 38 (78) 18 (86) 9 (83)
No. of metastatic sites
1 (%) 9 (18) 9 (42) 3 (25) P = 0.106
>2 (%) 40 (82) 12 (58) 9 (75)
Prior chemotherapy
Fluoropyrimidine
Refractory (%) 49 (100) 21 (100) 12 (100)
Intolerant (%) 0 (0) 0 (0) 0 (0)
Oxaliplatin
Refractory (%) 40 (82) 10 (48) 9 (75) P = 0.017
Intolerant (%) 9 (18) 11 (52) 3 (25)
Irinotecan P = 1.000
Refractory (%) 48 (98) 21 (100) 12 (100)
Intolerant (%) 1 (2) 0 (0) 0 (0) P = 0.669
Before bevacizumab therapy 25 (51) 9 (43) 7 (58)
Yes (%) 24 (49) 12 (57) 5 (42) P = 0.236
No (%) 12 5 25
Response rate for prior irinotecan-containing therapies (%)
Pathological classification
G1, G2 (%) 42 (86) 20 (95) 11 (92) P = 0.481
G3, G4 (%) 7 (14) 1 (5) 1 (8)

ECOG PS Eastern Cooperative Oncology Group performance status.

: Fisher’s exact test.

: Kruskal–Wallis test.

Bando et al.

Bando et al. BMC Cancer 2013 13:405   doi:10.1186/1471-2407-13-405

Open Data